ArticleCase reports in oncology

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer.

Tomoya YokotaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.